A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

December 5, 2024

Study Completion Date

December 31, 2025

Conditions
Mantle Cell Lymphoma (MCL)
Interventions
DRUG

Rocbrutinib

Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.

Trial Locations (43)

100089

Peking University Third Hospital, Beijing

100142

Beijing Cancer Hospital, Beijing

510060

Sun Yat-sen University Cancer Center, Guangzhou

Unknown

Anhui provincial cancer hospital, Hefei

The first affiliated hospital of Anhui medical university, Hefei

The first affiliated hospital of Chongqing mediacal university, Chongqing

Fujian Cancer Hospital, Fuzhou

Fujian Medical university union hospital, Fuzhou

The first affiliated hospital of Xiamen university, Xiamen

Gansu provincial cancer hospital, Lanzhou

Meizhou people'shospital, Meizhou

The First Affiliated Hospital of Guangxi Medical University, Nanning

The fourth hospital of Hebei medical university, Shijiazhuang

Harbin First Hospital, Harbin

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang

Henan Cancer Hospital, Zhengzhou

Henan provincial people's hospital, Zhengzhou

The first affiliated hospital of Zhengzhou university, Zhengzhou

Hunan cancer hospital, Changsha

Jiangsu cancer hospital, Nanjing

Jiangsu province hospital, Nanjing

The first affiliated hospital of Nanchang university, Nanchang

The second hospital of dalian medical university, Dalian

Shengjing hospital of China medical university, Shenyang

The first hospital of China medical university, Shenyang

Qilu hospital of Shandong university, Jinan

Shandong Cancer Hospital, Jinan

West China School of Medicine, Chengdu

Tianjin Hematonosis Hospital, Tianjin

Tianjin medical university cancer hospital, Tianjin

Zhejiang Cancer Hospital, Hangzhou

Affiliated hospital of hebei university, Baoding

Beijing Boren Hospital, Beijing

Beijing Friendship hospital, Beijing

The First Bethune Hospital of Jilin University, Changchun

Sichuan Cancer Hospital, Chengdu

The First People's Hospital of Foshan, Foshan

Nanfang Hospital, Southern Medical University, Guangzhou

Sun Yat-sen Memorial Hospital, Guangzhou

The First Affiliated Hospital of Soochow University, Suzhou

The first affiliated hospital of Wenzhou medical university, Wenzhou

Hubei Cancer Hospital, Wuhan

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY